Vyne Therapeutics Stock Analysis

VYNE -  USA Stock  

USD 0.64  0.01  1.59%

The big decline in price over the last few months for Vyne Therapeuticsmay raise some interest from shareholders as it is trading at a share price of 0.64 on 1,602,900 in trading volume. The company directors and management failed to add value to investors and positioning the company supply of money to exploit market volatility in December. However, diversifying your holdings with Vyne Therapeutics or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.35. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Vyne Therapeutics partners.
Also, please take a look at World Market Map.

Vyne Therapeutics Stock Analysis 

 
Refresh
The Vyne Therapeutics stock analysis report makes it easy to digest most publicly released information about Vyne Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Vyne Therapeutics Stock analysis module also helps to analyze the Vyne Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Vyne Therapeutics Stock Analysis Notes

About 30.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.6. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vyne Therapeutics recorded a loss per share of 1.75. The entity had not issued any dividends in recent years. The firm had a split on the 16th of February 2021. VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. Vyne Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 106 people. For more information please call the company at 800 775 7936 or visit https://www.vynetherapeutics.com.

Vyne Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Vyne Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Vyne Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Vyne Therapeutics generated a negative expected return over the last 90 days
Vyne Therapeutics has high historical volatility and very poor performance
Vyne Therapeutics has some characteristics of a very speculative penny stock
The company reported the previous year's revenue of 16.75 M. Net Loss for the year was (84.94 M) with profit before overhead, payroll, taxes, and interest of 19.6 M.
Vyne Therapeutics currently holds about 52.31 M in cash with (71.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.98, which can makes it an attractive takeover target, given it will continue generating positive cash flow.

Vyne Therapeutics Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Vyne Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vyne Therapeutics backward and forwards among themselves. Vyne Therapeutics' institutional investor refers to the entity that pools money to purchase Vyne Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Spire Wealth ManagementCommon SharesKK
Fny Investment Advisers LlcCommon Shares25.00.0
Vanguard Group IncCommon Shares2.4 M3.4 M
Perceptive Advisors LlcCommon Shares2.3 M3.2 M
Franklin Resources IncCommon Shares1.9 M2.7 M
Renaissance Technologies LlcCommon Shares1.2 M1.7 M
Dsc Advisors LpCommon Shares1.1 M1.5 M
Note, although Vyne Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Vyne Therapeutics Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 35.32 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vyne Therapeutics's market, we take the total number of its shares issued and multiply it by Vyne Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (40.86) % which means that it has lost $40.86 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (156.71) %, meaning that it created substantial loss on money invested by shareholders. Vyne Therapeutics management efficiency ratios could be used to measure how well vyne therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 23rd of January, Vyne Therapeutics has the coefficient of variation of (1,195), and Risk Adjusted Performance of (0.06). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vyne Therapeutics, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Vyne Therapeutics, which can be compared to its competition. Please validate Vyne Therapeutics variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Vyne Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 0.64 per share. As Vyne Therapeutics is a penny stock we also advise to double-check its total risk alpha numbers.

Vyne Therapeutics Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Exponential Moving Average is calculated by weighting recent values of Vyne Therapeutics more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Vyne Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vyne Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vyne Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vyne Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Zeronda Tyler over a month ago via Macroaxis 
Acquisition by Zeronda Tyler of 4187 shares of Vyne Therapeutics subject to Rule 16b-3
Zeronda Tyler over three months ago via Macroaxis 
Payment of 206 shares by Zeronda Tyler of Vyne Therapeutics subject to Rule 16b-3
Zeronda Tyler over three months ago via Macroaxis 
Acquisition by Zeronda Tyler of 60860 shares of Vyne Therapeutics subject to Rule 16b-3
Lepore Patrick G over three months ago via Macroaxis 
Purchase by Lepore Patrick G of 12500 shares of Vyne Therapeutics
Perceptive Advisors Llc over three months ago via Macroaxis 
Sale by Perceptive Advisors Llc of 250000 shares of Vyne Therapeutics
Perceptive Advisors Llc over three months ago via Macroaxis 
Sale by Perceptive Advisors Llc of 250000 shares of Vyne Therapeutics
Perceptive Advisors Llc over three months ago via Macroaxis 
Sale by Perceptive Advisors Llc of 338897 shares of Vyne Therapeutics
Sandoval Elisabeth over six months ago via Macroaxis 
Acquisition by Sandoval Elisabeth of 20500 shares of Vyne Therapeutics subject to Rule 16b-3
Zeronda Tyler over six months ago via Macroaxis 
Payment of 700 shares by Zeronda Tyler of Vyne Therapeutics subject to Rule 16b-3
Zeronda Tyler over six months ago via Macroaxis 
Vyne Therapeutics exotic insider transaction detected
Domzalski David over six months ago via Macroaxis 
Acquisition by Domzalski David of 941 shares of Vyne Therapeutics subject to Rule 16b-3
Lepore Patrick G over six months ago via Macroaxis 
Purchase by Lepore Patrick G of 12500 shares of Vyne Therapeutics

Vyne Therapeutics Predictive Daily Indicators

Vyne Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Vyne Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Vyne Therapeutics Forecast Models

Vyne Therapeutics time-series forecasting models is one of many Vyne Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Vyne Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Vyne Therapeutics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Vyne Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Vyne Therapeutics shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Vyne Therapeutics. By using and applying Vyne Therapeutics Stock analysis, traders can create a robust methodology for identifying Vyne Therapeutics entry and exit points for their positions.
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. Vyne Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 106 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Vyne Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Portfolio Comparator Now

   

Portfolio Comparator

Compare the composition, asset allocations and performance of any two portfolios in your account
All  Next Launch Module
Also, please take a look at World Market Map. Note that the Vyne Therapeutics information on this page should be used as a complementary analysis to other Vyne Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.

Complementary Tools for Vyne Therapeutics Stock analysis

When running Vyne Therapeutics price analysis, check to measure Vyne Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vyne Therapeutics is operating at the current time. Most of Vyne Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vyne Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Vyne Therapeutics' price. Additionally, you may evaluate how the addition of Vyne Therapeutics to your portfolios can decrease your overall portfolio volatility.
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Is Vyne Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne Therapeutics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne Therapeutics that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Vyne Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.